Skip to content
Study details
Enrolling now

Trial of Suvorexant for Sleep in Children With Autism

Stanford University
NCT IDNCT05546554ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

26

Study length

about 4.6 years

Ages

13–17

Locations

1 site in CA

What this study is about

Researchers are testing whether suvorexant helps children with autism sleep better. The trial will compare suvorexant to a placebo, using tests like polysomnography and actigraphy to measure sleep patterns. It will last 1664 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo
  • 2.Take Suvorexant

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

suvorexant

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change from baseline in sleep architecture as measured by polysomnography (PSG) and/or actigraphy, examples include sleep latency and non-rapid eye movement (NREM)

Secondary: Change from baseline in sleep efficiency as measured by actigraphy

Body systems

Psychiatry / Mental Health